PHL-SERTRALINE CAPSULE

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

SERTRALINE (SERTRALINE HYDROCHLORIDE)

Inapatikana kutoka:

PHARMEL INC

ATC kanuni:

N06AB06

INN (Jina la Kimataifa):

SERTRALINE

Kipimo:

50MG

Dawa fomu:

CAPSULE

Tungo:

SERTRALINE (SERTRALINE HYDROCHLORIDE) 50MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

250

Dawa ya aina:

Prescription

Eneo la matibabu:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0123417001; AHFS:

Idhini hali ya:

CANCELLED POST MARKET

Idhini ya tarehe:

2011-02-28

Tabia za bidhaa

PRODUCT MONOGRAPH
Pr
PHL-SERTRALINE
(Sertraline hydrochloride capsules)
25 mg, 50 mg and 100 mg
Sertraline, as sertraline hydrochloride
Antidepressant / Antipanic / Antiobsessional Agent
PHARMEL INC.
6111 Royalmount Ave., Suite 100
Montreal, Quebec
H4P 2T4
Date of Revision:
July 11, 2013
Submission Control No: 166014
Pr
_phl-SERTRALINE Product Monograph _
_Page 2 of 47_ PRODUCT MONOGRAPH
PR
PHL-SERTRALINE
(Sertraline hydrochloride Capsules)
25 mg, 50 mg and 100 mg
Sertraline, as sertraline hydrochloride
THERAPEUTIC CLASSIFICATION
Antidepressant - Antipanic - Antiobsessional Agent
ACTION
The mechanism of action of sertraline is presumed to be linked to its
ability to inhibit the
neuronal reuptake of serotonin. It has only very weak effects on
norepinephrine and dopamine
neuronal reuptake. At clinical doses, sertraline blocks the uptake of
serotonin into human
platelets.
Like most clinically effective antidepressants, sertraline
downregulates brain norepinephrine and
serotonin receptors in animals. In receptor binding studies,
sertraline has no significant affinity
for adrenergic (_alpha_
_1_
_, alpha_
_2_
_ & beta_), cholinergic, GABA, dopaminergic, histaminergic,
serotonergic (5-HT1A, 5-HT1B, 5-HT2) or benzodiazepine binding sites.
In placebo-controlled studies in normal volunteers, sertraline
hydrochloride did not cause
sedation and did not interfere with psychomotor performance.
Pharmacokinetics: Following multiple oral once-daily doses of 200 mg,
the mean peak plasma
concentration (C
max
) of sertraline is 0.19 µg/mL occurring between 6 to 8 hours
post-dose. The
area under the plasma concentration time curve is 2.8 mg hr/l. For
desmethylsertraline, C
max
is
0.14 µg/mL, the half-life 65 hours and the area under the curve 2.3
mg hr/l. Following single or
multiple oral once-daily doses of 50 to 400 mg/day the average
terminal elimination half-life is
approximately 26 hours. Linear dose proportionality has been
demonstrated over the clinical
dose range of 50 to 200 mg/day.
Food appears to increase the bioavailab